Free Trial!
Today’s Best Stocks To Trade! Click Here
As part of this 10 year agreement (with two additional five year renewal terms), Luitpold will continue to contract manufacture these products for Fresenius Medical Care. The transaction involves the payment of royalties by Fresenius Medical Care to Luitpold over the lifetime of the agreement, and Luitpold's payment of royalties to Vifor Pharma of St Gallen, Switzerland, which supplies the active pharmaceutical ingredient to Luitpold. Luitpold, through its subsidiary American Regent, will continue to sell Venofer for use in treating chronic kidney disease patients not yet on dialysis.
The agreement additionally includes a similar sublicense for the next generation of IV iron products for the US and Canada known as Injectafer (ferric carboxymaltose injection), which is expected to enhance the treatment of anemia in this same patient population through the application of innovative drug administration techniques.
Venofer a preparation of elemental iron in sucrose, is the only first line treatment option approved by the FDA for the intravenous treatment of both dialysis and non-dialysis chronic kidney disease (CKD) patients with iron deficiency anemia.
The transaction is subject to customary closing conditions including the expiration of the applicable waiting period under the Hart Scott Rodino Antitrust Act. The company anticipates closing this transaction in 2008.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
